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Abstract Evaluation of heterogeneity of treatment effect (HTE) is an essential aspect of
personalized medicine and patient-centered outcomes research. Our goal in this article is to
promote the use of Bayesian methods for subgroup analysis and to lower the barriers to
their implementation by describing the ways in which the companion software beanz can
facilitate these types of analyses. To advance this goal, we describe several key Bayesian
models for investigating HTE and outline the ways in which they are well-suited to address
many of the commonly cited challenges in the study of HTE. Topics highlighted include
shrinkage estimation, model choice, sensitivity analysis, and posterior predictive checking.
A case study is presented in which we demonstrate the use of the methods discussed.
Keywords Bayesian subgroup analysis  Heterogeneity of treatment effect  Hierarchical
modeling  Personalized medicine  Precision medicine  Treatment–covariate interaction
1 Introduction
The conventional focus of clinical trials has been on assessing the average effect of a
treatment in a target population. However, examining only the average treatment effect in
the presence of patient heterogeneity may mask important differences in treatment efficacy
or in treatment safety across subsets of patients. Heterogeneity of treatment effect (HTE)
refers to differences in treatment effectiveness attributable to observable patient attributes
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such as demographic characteristics, genetic characteristics, and other baseline risk factors.
For many diseases, understanding the extent and nature of treatment effect heterogeneity is
key to the development of improved treatment strategies more tailored to individual patient
needs.
Heterogeneous treatment effects are typically explored by examining patient outcomes
in mutually exclusive subgroups defined by observable patient characteristics. In cases
where a beneficial overall treatment effect has been found, such subgroup analyses are
performed to examine the consistency of the claimed treatment effect across major patient
sub-populations. Existence of subgroups that appear to respond differently to treatment can
affect inclusion criteria in later clinical trials or in labeling decisions for approved drugs
(Alosh et al. 2015). Though subgroup analyses are often recommended and routinely
performed, there are a number of concerns which lead many to interpret the results of
subgroup analyses with caution. As highlighted by many authors (Yusuf et al. 1991; Wang
et al. 2007; Berger et al. 2014), these include problems related to multiplicity, post-hoc
analyses performed after seeing the data (‘‘data-dredging’’), and small within-subgroup
sample sizes. Proper adjustments for multiplicity in subgroup analysis can result in sub-
stantial loss of power to detect differences across subgroups, and small subgroup-specific
sample sizes lead to highly variable estimates which frequently makes it challenging to
assess the source and magnitude of HTE. In addition to concerns about low power and
post-hoc analyses, conventional approaches to subgroup analysis have difficulty in char-
acterizing variation in treatment effect after a treatment interaction has been determined to
be present.
A Bayesian approach to HTE can address many of the common concerns with subgroup
analysis while also providing more informative characterizations of HTE. Among the more
compelling reasons to employ Bayesian methods for subgroup analysis is their excellent
estimation performance in multi-parameter settings. A key feature of most Bayesian
approaches to subgroup analysis is the inclusion of all subgroup-level treatment effects in
one joint model. Incorporating all treatment effects in one common probability model,
allows inferences in each subgroup to be driven by all the data rather than only the data in
that particular subgroup. This has the consequence of stabilizing highly variable subgroup
effect estimates by allowing these highly variable cases to ‘‘borrow information’’ from the
data in other subgroups. Moreover, the borrowing of information across subgroups
increases the precision of the individual estimates. The utilization of all the data alleviates
to a large extent the common problem in subgroup analysis of small within-subgroup
sample sizes and highly variable estimates. Indeed, these advantages of using Bayes
estimates in multi-parameter settings have been widely acknowledged (Efron and Morris
1973; James and Stein 1961) and represents one of the main areas in which Bayesian
methods can offer an improvement over other methods.
In addition to improved estimation and precision, the Bayesian framework can arguably
provide answers to questions more in line with the goals of personalized/patient-centered
medicine. Bayesian approaches naturally lend themselves to characterizations of HTE
because such heterogeneity may be directly expressed through the distribution of the
subgroup treatment effect parameters. While other approaches emphasize hypothesis
testing and detection of HTE, the Bayesian models discussed here have the built-in
assumption that HTE is present, and the statistical challenge is to estimate and characterize
this heterogeneity in treatment effect. The implications of the estimated variation in
treatment effect can then be evaluated taking into account posterior uncertainty, the prior
information used, and the context of the problem. The Bayesian framework is also useful in
its ability to automatically give direct probability statements to a wide range of questions
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of clinical interest. For example, from a personalized medicine perspective, a natural
question to ask is: what is the probability that individuals from a particular subgroup will
benefit from this treatment? A direct answer to such a question can be obtained from the
full posterior distribution without the need to refer to repeated sampling characteristics as
in frequentist inference. Addressing complex clinical questions such as these and providing
associated uncertainty measures is often challenging when operating outside the Bayesian
framework.
Our goal in this article is to promote the use of Bayesian methods for subgroup analysis
and to lower the barriers to their implementation by describing the ways in which the
companion software beanz can facilitate these types of analyses. To this end, we provide in
this paper an overview of the models implemented by the beanz software tool (Wang et al.
2016), describe their merits, and outline other important factors to consider when using
Bayesian methods for subgroup analysis. The web-based software tool beanz can be
accessed from https://www.research-it.onc.jhmi.edu/dbb/custom/A6/, and the R package
version of this software entitled beanz is available from the Comprehensive R Archive
Network (http://cran.r-project.org). Information regarding the usage and capabilities of
beanz is provided in greater detail in Wang et al. (2016), and a beanz software manual is
also available from the beanz website. This article is organized as follows. In Sect. 2, we
begin by introducing our motivating example—the SOLVD trial—and describe the key
patient subgroups to be investigated in our data analysis. In Sect. 3, we then review several
of the more conventional, frequentist approaches to subgroup analysis and examine their
application to the SOLVD trial. In Sect. 4, we introduce several Bayesian models sug-
gested in Jones et al. (2011) that can be used in subgroup analysis and describe several of
their prominent features. Throughout this section, the Bayesian methods for subgroup
analysis are illustrated through their use in analyzing the SOLVD data, and we compare
and contrast the results of both the frequentist and Bayesian approaches. Connections
between the data analysis and the capabilities of the beanz software are also emphasized
throughout this section. Remarks regarding multiplicity issues in Bayesian subgroup
analysis are made in Sect. 5, and Sect. 6 describes approaches for model comparison and
model checking. We conclude in Sect. 7 with a few final remarks.
2 Motivating example: the SOLVD trial
The studies of left ventricular dysfunction (SOLVD) described in The SOLVD Investi-
gators (1991) examined the impact of the drug Enalapril in a group of patients with
congestive heart failure and low ejection fraction. In total, 2569 patients were enrolled in
the treatment trial with 1285 patients being assigned to the treatment arm and 1284 patients
being assigned to the placebo arm. After the scheduled end of the study, 510 patients had
died in the placebo group while 452 had died in the Enalapril group.
Due to the importance of ejection fraction in determining the target population, we
examine response to treatment in subgroups defined by baseline ejection fraction, gender,
and age. We dichotomized age into B65 and [65 years subgroups, and we discretized
baseline ejection fraction by tertiles as was done in the original paper (The SOLVD
Investigators 1991) describing this study. This way of discretizing age and ejection fraction
yielded 12 subgroups in total. One patient was dropped from our analysis due to a missing
ejection fraction value. Table 1 shows cross-tabulations for each of the variables used in
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the subgroup analysis, and Fig. 1 shows the number of patients within each of the 12
subgroups.
The original paper reporting on this study (The SOLVD Investigators 1991) concluded
that the addition of Enalapril to standard therapy had a positive impact on patient mortality
Table 1 Number of patients by
treatment and subgroup
covariates
Subgroup Enalapril Placebo Total
Gender
Female 259 244 503
Male 1025 1040 2065
Age
B65 866 862 1728
[65 418 422 840
Ejection fraction
6–22 468 474 942
23–29 407 417 824
30–35 409 393 802
treatment effect
−1.25 −1 −0.75 −0.5 −0.25 0 0.25 0.5 0.75 1
low ≤ 65 Female 108
medium ≤ 65 Female 92
high ≤ 65 Female 107
low > 65 Female 54
medium > 65 Female 62
high > 65 Female 80
low ≤ 65 Male 563
medium ≤ 65 Male 459
high ≤ 65 Male 399
low > 65 Male 217
medium > 65 Male 211
high > 65 Male 216




Fig. 1 Basic shrinkage model. SOLVD data. Posterior means and frequentist estimates for each of the 12
subgroups defined by the variables gender, age, and ejection fraction. Frequentist estimates h^g and
associated 95% confidence intervals are in black while Bayes estimates and associated 95% credible
intervals are in red. The solid vertical line represents the estimated overall treatment effect from the basic
shrinkage model, namely, the posterior mean of s (Color figure online)
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and hospitalization. Fitting a Cox-proportional hazard model using patients from the
treatment trial supports this conclusion; the estimated log-hazard ratio of the Enalapril
group to the control group was 0:32 with an associated standard error of 0.06. The
survival endpoint used here and throughout the paper is time-to-death or hospitalization.
While Enalapril appears to have had a beneficial overall effect in this trial, we are mainly
interested in exploring any treatment effect heterogeneity in terms of key baseline
covariates.
3 Frequentist methods for subgroup analysis
3.1 Univariate subgroup analysis
Univariate tests of interaction investigate each variable one-at-a-time to determine if there
is an interaction between treatment and the specified variable. Because any such treatment
interaction is an indication that the treatment effect varies across the levels of a subgroup
variable, interaction tests are deemed important in assessing consistency of treatment effect
across patient subgroups. Indeed, the FDA Guidance for Industry (see Food and Drug
Administration 1998; Varadhan and Wang 2014) states that investigators provide evidence
for ‘‘consistency across key patient subsets’’ in order to address concerns about the gen-
eralizability of trial results.
Suppose that for subjects ð1; . . .; nÞ we have observed continuous outcomes y ¼
ðy1; . . .; ynÞ and assigned treatments T1; . . .; Tn with either Ti ¼ 0 or Ti ¼ 1. Suppose fur-
ther that the jth covariate has K(j) levels and Xijk is an indicator of whether or not patient i
has the ðk þ 1Þst level of the jth covariate. Then, in the following regression for the
expected outcome







a univariate test of interaction (for the jth covariate) tests the null hypothesis
H0 : c1 ¼    ¼ cKðjÞ1 ¼ 0. In other words, a univariate test of interaction (for the jth
covariate) tests whether or not the effect of treatment is the same across all levels of the jth
covariate. Analogous univariate tests may be performed for other types of responses such
as binary or time-to-event outcomes.
To test for consistency of effect across the key identified patient subgroups in the
SOLVD trial, we separately performed univariate tests of treatment interaction using the
variables age, gender, and baseline ejection fraction. For each variable, we tested whether
or not the variable–treatment interaction coefficients were all equal to zero or not. Because
the outcomes in SOLVD are time-to-event, we used a Cox-proportional hazard models
where the regression equations for the hypothesis tests were as in (1). These tests yielded
p-values 0.40, 0.034, and 0.029 for age, gender, and ejection fraction respectively. At first
glance, these results suggest there are treatment interactions with gender and ejection
fraction which could raise doubts about the consistency of treatment effect. However,
when performing a series of univariate tests, it is important to adjust for the multiplicity of
tests (see, e.g. Varadhan and Wang 2014), and when using the Bonferroni adjustment for
multiplicity, the adjusted p values for gender and ejection fraction were 0.102 and 0.087
respectively which considerably weakens the evidence for lack of consistency.
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Despite their effectiveness in detecting the presence of interactions, univariate one-
variable-at-a-time interaction tests have several limitations that restrict their usefulness in
assessing treatment effect heterogeneity. Firstly, univariate interaction tests are not, in
general, able to determine the direction or the magnitude of the treatment interaction of
interest (see e.g., Alosh et al. 2015). When the variable in question has more than two
levels, an interaction test can only lead to the conclusion that the treatment effects are not
the same in all the subgroups but cannot detect the direction of treatment effect changes.
Even when there are only two subgroup levels, interaction tests are not well-suited for
assessing the magnitude of an interaction effect. Estimates of effect are often highly
variable for small subgroups and are biased when only examined after they yield a sig-
nificant result. As a result, it can be difficult to judge the importance of the treatment effect
difference between two subgroups even when an interaction test yields a significant result.
3.2 Unstructured interaction tests
An additional concern with univariate analyses is that they ignore the correlation among
patient characteristics and examine each variable in isolation. As noted by Kent and
Hayward (2007), a limitation of univariate subgroup analysis is that the univariate sub-
groups are less likely to identify important heterogeneity in treatment effect since the
subgroups only differ in terms of a single characteristic. Overlooking such structure in the
correlation among subgroups can result in confounding and other misleading inferences
(Varadhan and Wang 2014). For example, suppose that the effectiveness of a drug varies
by body weight independently of gender. In this case, an apparent marginal treatment–
gender interaction would be largely driven by differences in treatment effectiveness by
weight despite there being no difference in treatment response by gender when adjusting
for body weight. This concern can be addressed by performing an unstructured interaction
test (Kovalchik et al. 2013) where all patient covariates are included rather than focusing
on one covariate at a time as is done in univariate analyses. In particular, using notation as
in (1), an unstructured interaction test will test the null hypothesis that all cjk equal zero in
the following regression model for the expected outcome











In contrast to the univariate one-at-a-time approach, the full unstructured interaction
approach tests whether or not there is at least one treatment–subgroup interaction when all
of the other covariates are present in the model. However, as with univariate interaction
tests, an unstructured interaction test can only determine if a treatment interaction is
present, and a rejection of the test does not directly indicate which subgroups are the source
of the interaction and does not characterize the magnitude of the subgroup treatment effect
differences.
Using the SOLVD data with the same three covariates of age, gender, and ejection
fraction, we performed a full, unstructured interaction test. For this test, we used a Cox-
proportional hazards model with a regression formulation as in (2). This test yielded a
p value of 0.018 suggesting that the treatment effect may not be constant across all
subgroups. Summary output from a fit of the full interaction model is shown in Table 2.
A fully stratified subgroup analysis calculates treatment effects in each subgroup
combination of the patient covariates. For example, if there are two covariates—gender
(male/female) and age (young/old), then a fully stratified analysis reports the results for
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each of the four possible subgroups. While addressing some of the problems with uni-
variate one-at-a-time analyses, fully stratified analyses will typically have much smaller
subgroup-specific sample sizes and highly variable subgroup effect estimates.
4 Bayesian methods for subgroup analysis
4.1 Sampling model and notation
In the following description of subgroup analysis, we assume that summary statistics
ðh^g; s2gÞ have been computed for each of the mutually exclusive subgroups g ¼ 1; . . .; G.
The estimates h^g are typically fully stratified frequentist estimates with the statistic h^g
representing an estimate of the treatment effect in subgroup g and sg representing the
standard error associated with h^g. Reduction of data to the form ðh^g; s2gÞ includes a wide
range of possible settings including, for example, cases where h^g is a difference of treat-
ment means, cases where h^g represents an estimated log-odds ratio, or cases where h^g is an
estimated log-hazard ratio. The beanz web-based software tool allows the user to either
input subgroup-level summary statistics ðh^g; s2gÞ or to input the subject-level raw data, in
which case beanz computes the necessary summary statistics for each subgroup.
Often, h^g may be interpreted as a maximum likelihood estimate of the underlying
treatment effect of interest hg, and as such, standard statistical theory asserts that a good
approximation to the sampling distribution of h^g is
h^gjhg Normal hg; s2g
 
: ð3Þ
One criticism of (3) is that it ignores the uncertainty about the variance of h^g and simply
plugs-in an estimate s2g of this variance. However, in the absence of additional information
beyond ðh^g; s2gÞ, (3) serves as a suitable approximation in most cases and may be preferable
to inappropriate modeling of the uncertainty associated with sg. Indeed, several authors
including Jones et al. (2011) suggest using the sampling distribution in (3) as a reasonable
approximation.
For the SOLVD data, we define the subgroup treatment effect hg as the log-hazard ratio
between the treatment (Enalapril) group and the placebo group which implies that smaller
Table 2 Cox proportional haz-
ards model the covariates: treat-
ment, age, gender, baseline
ejection fraction, and the inter-
actions between treatment and





Coefficient SE z-value p value
trtment -0.183 0.147 -1.242 0.214
age[65 0.251 0.078 3.225 0.001
genderMale 0.153 0.095 1.605 0.108
ejecfrac-medium -0.291 0.087 -3.365 0.001
ejecfrac-high -0.638 0.093 -6.894 \0.001
trtment:age[65 -0.121 0.116 -1.045 0.296
trtment:Male -0.278 0.139 -1.998 0.046
trtment:ejecfrac-medium 0.112 0.129 0.868 0.386
trtment:ejecfrac-high 0.354 0.136 2.601 0.009
Health Serv Outcomes Res Method (2016) 16:213–233 219
123
treatment effects correspond to greater treatment benefit. The treatment effect estimates h^g
and associated standard errors sg were computed by fitting a Cox-proportional hazards
model within each of the G ¼ 12 subgroups. The estimated treatment effect h^g is the
estimated log-hazard ratio between the Enalapril and placebo groups. It is worth men-
tioning that the treatment effect estimates h^g were computed using time-to-death or hos-
pitalization as the outcome while the example on the beanz website involving the SOLVD
data currently uses time-to-death or hospitalization after 1 year of follow-up as the out-
come. In beanz, when the responses are time-to-event and when the user inputs the
original, subject-level data rather than subgroup-level summary statistics, beanz computes
estimated log-hazard ratios h^g and standard errors sg by fitting a Cox-proportional hazards
model within each of the defined subgroups.
4.2 The basic shrinkage model
4.2.1 Model description
The basic shrinkage model is a general approach for analyzing variation in treatment
effect. This model is employed in a wide range of applications and is particularly suited to
settings such as subgroup analysis where one is interested in separate units of analysis with
each unit having a relatively small sample size. Its effectiveness in these settings is largely
due to the ‘‘partial-pooling’’ or ‘‘shrinkage’’ phenomenon where individual subgroup effect
estimates are shrunken towards an overall global mean. Despite its reliance on the often
implausible assumption of full exchangeability, the basic shrinkage model is a useful
starting point because it illustrates many recurring themes of Bayesian analysis and
because it frequently serves as an effective and robust approximation. Moreover, from the
perspective of analyzing HTE, the exchangeability assumption serves as a reasonable
a-priori position since it does not make any a-priori distinctions among the subgroup-level
treatment effects.
The basic shrinkage model starts with the sampling model of (3) for the observed effect
estimates h^g and adds the assumption that the underlying subgroup treatment effects hg are
drawn from a common normal distribution with mean s and standard deviation x. A fully
hierarchical approach places a prior on the hyperparameters s and x, and as in Jones et al.
(2011), we suggest a normal prior for s and a half-normal prior for x in order to complete





In the above, the parameter s should be thought of as the true overall or average treatment
effect and x should be thought of as the standard deviation of the treatment effect across
subgroups. Thus, larger values of x indicate greater treatment effect heterogeneity. When
x is treated as a fixed quantity, (4) is commonly referred to as a one-way random effects
model. Models similar to (4) are popular in random-effects meta-analysis (see e.g., Sutton
and Abrams 2001) where the parameters hg are thought of as study-specific treatment
effects drawn from a common population distribution, which in the case of model (4) is
assumed to be Normalðs;x2Þ. In the absence of substantial prior information regarding
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possible values of s and x, it is recommended to start with diffuse priors for s and x (i.e.,
large r2s and r
2
x) in order to accommodate a wide range of values for both the overall
treatment effect and the variation across subgroups.
In practice, the basic shrinkage model can be thought of as providing a compromise
between the fully stratified, separate analysis described at the end of Sect. 3 and a com-
pletely pooled analysis which ignores any differences among subgroups and only reports
the overall response to treatment. In contrast to these two extremes, estimates of the within-
subgroup treatment effects in the basic shrinkage model are determined by both the fully
stratified estimate h^g and the overall treatment effect estimate s^. In particular, in the basic
shrinkage model, each estimate of the subgroup-level treatment effect is a weighted
average of the original subgroup-specific estimate h^g and the global treatment effect
estimate which causes each Bayesian estimate to be pulled or ‘‘shrunken’’ towards the
estimated overall treatment effect. This shrinkage phenomenon may be more clearly
observed by looking at the form of the posterior mean of hg
E hgjy








where s^ ¼ EðsjyÞ is the posterior mean of the overall treatment effect. In other words,
EðhgjyÞ is equal to the overall treatment effect estimate plus a proportion of the distance
between h^g and s^. The posterior mean of the fraction rðx; sgÞ ¼ x2=ðx2 þ s2gÞ determines
the magnitude of shrinkage with Eðrðx; sgÞjyÞ ¼ 0 implying complete shrinkage to the
overall treatment effect and E rðx; sgÞjy
  ¼ 1 implying no shrinkage at all. The fact that
rðx; sgÞ increases with x and decreases with sg has two important consequences: sub-
groups with high estimation variance (i.e., higher sg) are shrunk more severely than sub-
groups with low estimation variance, and small values of x are associated with stronger
overall shrinkage effects. The greater shrinkage for those subgroups with higher estimation
error is a reflection of the association between data sparsity and shrinkage effects. That is,
subgroups with large sample sizes and consequent estimation precision are treated as more
reliable estimates and are not shrunken much towards the overall effect estimate. Turning
to the role of x, because small values of x indicate little heterogeneity in treatment effect it
should not be surprising that selecting a prior for x with most of the probability near zero
will induce greater shrinkage across subgroups resulting in tighter clustering of subgroup
effects near s^. Indeed, setting a prior for x which is concentrated near zero is an effective
approach for expressing prior skepticism regarding the presence of treatment effect
heterogeneity.
The shrinkage phenomenon and information sharing across subgroups arises from the
shared normal distribution of the underlying treatment effects hg. Because this distribution
acts as a kind of common prior for each specific subgroup effect hg, this enables an
estimate for a specific subgroup g to partly ‘‘learn’’ from the evidence provided by the
outcomes in the other subgroups rather than only using the data from subgroup g. For
instance, if the majority of other subgroup effect estimates are tightly centered around s^,
larger values of h^g will tend to be pulled back towards the overall estimate because the
evidence from the other subgroups suggests there is very little heterogeneity in treatment
effect. This information sharing has the consequence of dampening the more extreme
subgroup outcomes that often occur when there are small within-subgroup sample sizes.
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Figure 1 presents an application of the basic shrinkage model to the 12 subgroups from
the SOLVD trial. The figure shows, for each of the 12 subgroups, estimates h^g of the log-
hazard ratio between two treatments of interest along with the corresponding posterior
means and 95% credible intervals obtained from the basic shrinkage model. The solid
vertical line placed at 0:30 in Fig. 1 corresponds to the posterior mean s^ of s from the
basic shrinkage model. The estimate s^ can be interpreted as the estimated overall treatment
effect from the basic shrinkage model, and as is usually the case, this estimate s^ ¼ 0:30 is
quite close to the overall treatment effect estimate of 0:32 obtained from fitting a Cox
proportional hazards model without any adjustment for baseline covariates. In addition to
nicely demonstrating the shrinkage of the Bayes estimates towards the estimated overall
treatment effect, Fig. 1 shows the usual greater precision of the Bayes estimates compared
to the raw, un-shrunken treatment effect estimates. Another feature of Fig. 1 worth
highlighting is the differential shrinkage across subgroups where, due to higher estimation
variance, treatment effect estimates for subgroups with fewer numbers of patients tend to
be shrunk more strongly. Differential shrinkage can sometimes result in cases where a
ranking of the Bayes estimates is different than that of the original frequentist estimates. In
fact, an example of this may be seen in Fig. 1 by comparing the (low ejec.frac./age[65/
female) subgroup and the (medium ejec.frac./age [65/male) subgroup. The original
treatment effect estimate for the (low ejec.frac./age[65/female) subgroup is more extreme
than that of the (medium ejec.frac./age[65/male) subgroup, but the greater shrinkage of
the highly variable (low ejec.frac./age[65/female) subgroup estimate results in the Bayes
estimate for the (low ejec.frac./age[65/female) subgroup being closer to s^ than the Bayes
estimate for the (medium ejec.frac./age [65/male) subgroup. The beanz software tool
automatically generates forest plots similar to Fig. 1 for each of the Bayesian models that
the user chooses to fit.
Overall, Fig. 1 demonstrates substantial shrinkage of the fully stratified frequentist
estimates with particularly strong shrinkage for the female subgroups. With this strong
shrinkage towards the overall treatment effect there appears to be little evidence of par-
ticular subgroups that have a substantially different response to treatment. There does,
however, appear to be greater treatment effectiveness in men versus women and in sub-
groups with lower baseline ejection fraction. In addition to looking at the variation in
treatment effect across subgroups, another key question is whether or not there are sub-
groups where the treatment effect has a different sign than the overall effect. On this issue,
there is little evidence from the basic shrinkage model of such qualitative interactions. All
of the posterior means are less than zero with the most modest estimated treatment effect of
0:12 occurring in the (medium ejec.frac./age B65/female) subgroup. This stands in
contrast to the frequentist estimates where the overall picture is not quite as coherent.
Three of the frequentist point estimates are positive, and one of the subgroup confidence
intervals does not cover the overall treatment effect of 0:30. Although the extreme point
estimates for subgroups (high ejec.frac./age[65/female) and (medium ejec.frac./age B65/
female) seem to point at interesting subgroup effects, such results should not be especially
surprising when analyzing a collection of highly variable estimates. The variation exhibited
by the un-shrunken estimates is usually much greater than the variation of the underlying
true treatment effects, and extreme values of the un-shrunken estimates should be viewed
with considerable skepticism. Subgroups with small numbers of patients tend to have the
highest variance, and indeed, as shown in Fig. 1, the two previously highlighted subgroups
with extreme point estimates of treatment effect [i.e., the (high ejec.frac./age[65/female)
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and (medium ejec.frac./age B65/female) subgroups] are among the smallest subgroups of
the 12 subgroups.
4.2.2 Role of priors and sensitivity analysis
Implementation of the basic shrinkage model requires a choice of the hyperparameters r2s
and r2x which refer to the priors for the overall treatment effect and the variation in
subgroup-specific treatment effect respectively. As a sensible default choice, we recom-
mended using ‘‘non-informative’’ priors for both s and x so that posterior inferences are
not unduly influenced by information not contained in the data being analyzed. Non-
informative priors are often implemented by choosing a vague or diffuse proper prior that
spreads the prior evenly over a broad range of possible values. For the overall treatment
effect s, one can specify a diffuse prior by choosing a large value of r2s such as r
2
s ¼ 106
recommended in Jones et al. (2011) or r2s ¼ 103 as is the default setting in beanz. As
stated in Eq. (4), the standard deviation of treatment effect across subgroups is determined
by the parameter x which is assigned a half-normal prior with parameter r2x. To assess the
plausibility of different values of r2x, it is helpful to recall the definition of a half-normal
distribution. The random variable Y is said to have a half-normal distribution with
parameter b2 (i.e., Y Half  Normalðb2) ) if Y has the same distribution as b|Z| where Z is
a standard normal random variable. This definition implies the median of the prior for x is
0:674  rx, the 75th percentile is 1:150  rx, and the 99th percentile is 2:576  rx.
Densities of half-normal distributions for several values of rx are shown in Fig. 2.
In the context of selecting an approximately non-informative half-normal prior for the
random effects standard deviation x when the treatment effects are mean differences,
Gelman (2006) suggests setting rx ¼ 100. In other contexts where the parameters of
interest are on a different scale, it may be sensible to use a more informative prior. As
noted by Spiegelhalter et al. (2003) and others, when hg represents a log-odds ratio setting
rx ¼ 1 is a reasonable choice since a standard deviation greater than three in the log-odds
ratio across subgroups would be considered quite large in almost any context. The half-
normal prior with rx ¼ 1 can then be viewed as a weakly informative prior in the sense










Fig. 2 Half-normal densities plotted for several values of the scale parameter: rx ¼ 1=2, rx ¼ 1, rx ¼ 2,
and rx ¼ 5
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that it is does not utilize any prior information specific to the problem at hand but only uses
what is known about the scale to construct a prior which gives most of its weight to all the
plausible values on this scale. Using the half-normal prior rather than more traditional non-
informative priors can have an impact on posterior inferences especially for cases when
there are few subgroups or for cases when the variation in treatment effect across sub-
groups is close to zero. In any setting, it is important to think about the scale on which the
outcome is measured and the interpretation of the corresponding parameters and priors. As
the default settings of r2s and r
2
x in the basic shrinkage model, beanz uses r
2
s ¼ 1000 and
r2x ¼ 100, but these values of the hyperparameters can be adjusted by the user in the
configuration panel of the beanz software tool.
Regardless of the choice of prior, it is advisable to conduct some type of sensitivity
analysis to examine the impact of changing the prior or other features of the model on
posterior inferences of interest. In the context of the basic shrinkage model, one way to
investigate the sensitivity of the results is to consider a range of values for the hyperpa-
rameter rx and compute posterior quantities such as subgroup-specific posterior means and
posterior quantiles for each value of rx. In this case, no practical changes in the main
inferences is an indication of robustness of these inferences to prior specification. If some
of the posterior inferences do change substantively in a sensitivity analysis, fitting the
model for several different priors will still enable one to analyze and report which con-
clusions are dependent on which features of the prior. One can then use this information to
further evaluate the strength of any claimed effect; for instance, reporting that a subgroup
seems to have a positive treatment effect except when using a highly skeptical prior for s
may be a useful conclusion and worth reporting. Here, a skeptical prior (see e.g.,
Spiegelhalter et al. 2003) for the overall treatment effect refers to a prior which is heavily
concentrated near zero and where large treatment effects are viewed skeptically and hence
given small prior probability.
As discussed in Sect. 4.2.1, the basic shrinkage model results shown in Fig. 1 provide
evidence against any substantial differences across subgroups though there is perhaps some
evidence of reduced treatment benefit in women and in those with higher ejection fraction
levels. To probe the sensitivity of these conclusions to sensible changes in the model, we fit
the basic shrinkage model for several different choices for the distribution of the variance
component x. We focused on the distribution of x because the choice of the variance
component distribution often has a meaningful impact on posterior inferences particularly
when there are few subgroups and/or when the variation in treatment effect is close to zero.
When varying the distribution of x for this sensitivity analysis, we used several dif-
ferent half-normal distributions along with the approximate Jeffreys prior suggested by
Dixon and Simon (1991). Posterior means and associated credible intervals are shown in
Fig. 3. Changing the value of rx in the half-normal distribution seems to have very little
impact even though this parameter was varied from 0.1 to 100. Using an approximate
Jeffreys prior for x also does not seem to have much of an impact when compared to the
half-normal priors. With regard to the approximate Jeffreys prior, it is worth mentioning
that there seems to be moderate sensitivity to the choice of the truncation point (i.e., 0.005
in the caption of Fig. 3) and that only the results for the truncation point suggested by
Dixon and Simon (1991) are shown in Fig. 3. The approximate Jeffreys prior suggested by
Dixon and Simon (1991) is used here because the true Jeffreys prior in this context is an
improper prior. In this case study, we have examined 12 subgroups. Posterior inferences
will likely be more sensitive to the prior for x when there are fewer subgroups because, in
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these case, there is not much information regarding the variation in treatment effect across
subgroups.
Embedded in the basic shrinkage model is the assumption of exchangeability of the
subgroup treatment effects. This means that, a-priori, there is no reason to favor any
specific subgroup or to group any collection of subgroups in a particular way. Essentially,
the exchangeability assumption is one that must be made if the subgroups were simply
labeled 1; . . .; G without any further information about the covariates which make up the
subgroups. Exchangeability is often a reasonable assumption, for example, when the
subgroups are defined by the levels of one variable and there is no prior information
suggesting that the treatment effects will be larger in any specific subgroup. In other
contexts, exchangeability may be seen as simply a reasonable working assumption. More
flexible modeling which relaxes the assumption of exchangeability can be done by
employing regression models for the subgroup treatment effects, which are discussed in the
following subsection.
treatment effect
−0.75 −0.5 −0.25 0 0.25 0.5
low ≤ 65 Female 108
medium ≤ 65 Female 92
high ≤ 65 Female 107
low > 65 Female 54
medium > 65 Female 62
high > 65 Female 80
low ≤ 65 Male 563
medium ≤ 65 Male 459
high ≤ 65 Male 399
low > 65 Male 217
medium > 65 Male 211
high > 65 Male 216
Ejec.Frac. Age Gender Size
Sbgrp
ω ~ Half−N( 0.1 )
ω ~ Half−N( 1 )
ω ~ Half−N( 100 )
ω ~ Jeffreys
Fig. 3 Basic shrinkage model—sensitivity to choice of prior. SOLVD data. Posterior means and associated
credible intervals for the following choices of the prior for x: xHalf  Normalð0:1Þ,
xHalf  Normalð1Þ, xHalf  Normalð100Þ, and x Jeffreys. The approximate Jeffreys prior for
x2 employed here is pðx2Þ / x2 for x2  0:005 and pðx2Þ ¼ 200 otherwise




Compared to the basic shrinkage model, regression models for the treatment effects offer a
more flexible way to represent the influence of each variable on the subgroup-specific
treatment effects and to capture the relationships among the subgroups. One of the most
straightforward regression models assumes that each subgroup treatment effect can be
expressed as a linear combination of individual variable effects. In particular, the rela-
tionship between the subgroup treatment effect hg and the variables that compose subgroup







where KðjÞ 2 is the number of levels of variable j and where Xgjk ¼ 1 when the ðk þ 1Þst
level of variable j belongs to subgroup g and Xgjk ¼ 0 otherwise. In the parameterization of
(6), s no longer represents the overall treatment effect but, rather, represents the treatment
effect in the subgroup where each variable has the reference level (i.e., level 1). The
regression coefficient bjk should then be interpreted as the change in the treatment effect
when variable j moves from the reference level to level k þ 1. For the SOLVD data, the
reference level used for the gender variable was female; the reference level used for the age
variable was age B65; and the reference level used for the ejection fraction variable was
the high ejection fraction category.
In the context of using (6) for subgroup analysis, Dixon and Simon (1991) suggest
basing the prior on the assumption that the regression coefficients are drawn from a
common normal distribution with mean zero and standard deviation x, and the authors
assign x2 the approximate non-informative Jeffreys prior pðx2Þ / ½maxfx2; eg1, where
e is a small, positive quantity. If, as in Jones et al. (2011), we replace the Jeffreys prior for





In comparison to estimates of bjk computed in the classical approach to regression, the
shared distribution of the regression coefficients in the Dixon–Simon specification shrinks
the posterior means of bjk towards zero. In addition to inducing desirable shrinkage of
subgroup treatment effects, the regression model (6) is able to better account for the
correlation that exists among subgroups than the basic shrinkage model. For example,
suppose we have subgroups defined by the two variables gender (male/female) and age
(young/old). If we consider subgroup g (female/young) and subgroup g0 (female/old), the
treatment effects for these two subgroups using the regression model (6) would be
hg ¼ sþ b11
hg0 ¼ sþ b11 þ b21:
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Correlation between these two subgroups is induced through the shared intercept s and
shared gender coefficient b11. Moreover, the regression structure implies that subgroups
which are ‘‘further apart’’ have less correlation than more closely related subgroups. For
instance, the prior correlation between the subgroups (female/young) and (female/old) is
greater than that between subgroups (female/young) and (male/old) since the former pair
share the coefficients ðs; b11Þ while the latter pair only share the intercept term. This richer
correlation structure of the Dixon–Simon model stands in contrast to the basic shrinkage
model which models the correlation equally across all subgroups. As in the basic shrinkage
model, we suggest using diffuse priors as the default choices for both the intercept s and
the regression coefficients. This can be done by choosing relatively large values of r2s and
r2x such as 1000 and 100 respectively.
4.3.2 Other regression models and the extended Dixon–Simon model
A number of other regression models for subgroup analysis have been suggested in Jones
et al. (2011) and implemented in the beanz software tool. These include a basic regression
model which places diffuse priors on the coefficients without a shared variance component,
and a basic regression and shrinkage model which adds a regression component to the
basic shrinkage model. Descriptions of these additional regression models are provided in
Wang et al. (2016).
In addition to these, beanz implements an extension of the Dixon–Simon model sug-
gested in Jones et al. (2011) which allows for higher orders of interaction between the
patient covariates. In the case of three covariates with two levels each, for example, the









cjhXgj1Xgh1 þ dXg11Xg21Xg31: ð7Þ
The regression coefficients for each order of interaction in (7) are assigned a Normal
distribution with a common variance. In particular, the priors for the model parameters in
(7) are sNð0; r2sÞ, bj1jx1 Nð0;x21Þ, cjhjx2 Nð0;x22Þ, and djx3 Nð0;x23Þ. The
variance components x1;x2;x3 are assigned independent half-normal priors.
Figure 4 shows posterior means and 95% credible intervals obtained from applying the
extended Dixon–Simon model [Eq. (7)] to the SOLVD data. Quantities from the basic
shrinkage model along with the fully stratified frequentist estimates are also displayed in
Fig. 4. It can be seen from this figure that the treatment effect estimates from the extended
Dixon–Simon model exhibit somewhat more variability than the estimates from the basic
shrinkage model. The most notable difference between the two Bayesian models in Fig. 4
is the reduced treatment effectiveness in women with medium or high ejection fraction
levels suggested by the extended Dixon–Simon model. This is because, whereas the basic
shrinkage model treats the subgroup categories as completely exchangeable labels, the
regression structure of the extended Dixon–Simon model is able to better recognize that
subgroups with higher ejection fraction levels consistently tend to respond worse to
treatment and that male subgroups consistently respond better to treatment.
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5 Multiple comparisons
A chief concern in subgroup analysis is the multiple comparisons that arise from the
various subgroups being considered. When using conventional approaches to hypothesis
testing, the probability of falsely rejecting at least one of the no-interaction hypotheses
grows as the number of subgroups increases, and failure to take this multiplicity into
account can result in high error rates. Traditional approaches to handling multiplicity
include reporting Bonferroni-adjusted p-values for each test performed, or adjustments that
increase confidence interval widths. Despite their role in controlling Type I errors, such
multiplicity adjustments can result in increased Type II errors and loss of power.
Tests of point hypotheses such as those discussed in Sect. 3 that test whether or not
specific interaction terms are exactly equal to zero are not applicable within the context of
the Bayesian models discussed thus far. The supposition in these models is that there is
variation in treatment effect across subgroups, and they assign zero probability to the
hypothesis that the parameters equal any particular value. Nevertheless, there may be
concern about making certain erroneous statements regarding subgroup differences; for
treatment effect
−1.25 −1 −0.75 −0.5 −0.25 0 0.25 0.5 0.75 1
low ≤ 65 Female 108
medium ≤ 65 Female 92
high ≤ 65 Female 107
low > 65 Female 54
medium > 65 Female 62
high > 65 Female 80
low ≤ 65 Male 563
medium ≤ 65 Male 459
high ≤ 65 Male 399
low > 65 Male 217
medium > 65 Male 211
high > 65 Male 216





Fig. 4 Extended Dixon–Simon model. SOLVD data. Posterior means and credible intervals for each of the
12 subgroups defined by the variables: gender, age, and baseline ejection fraction. Point estimates and
uncertainty intervals from the basic shrinkage model and from the fully stratified frequentist analysis are
also shown
228 Health Serv Outcomes Res Method (2016) 16:213–233
123
example, claiming that a subgroup-specific treatment effect is positive when the true
treatment effect is actually negative.
In the context of the basic shrinkage model, making explicit adjustments for multiplicity
is usually not necessary. Rather, one can just compare the individual credible intervals with
the threshold of interest without taking into account the number of subgroups considered in
the analysis. This is because shrinkage of more highly variable subgroup estimates tends to
not only produce more reasonable point estimates of treatment effect but also prevents
more ‘‘false positive’’ cases. As noted in Gelman (2006), Bayes procedures from hierar-
chical models that make no explicit multiplicity adjustments typically tend to be quite
conservative when compared to their classical counterparts. This conservatism of Bayes
estimates is exhibited in Fig. 1 where one can note that the posterior means from the basic
shrinkage model tend to not deviate much from the estimated overall treatment effect.
Because such automatic multiplicity adjustments arise from the joint modeling of the
subgroup effects, such claims are dependent upon a well-calibrated model, and one should
perform checks to ensure that the model used is justifiable. Approaches for model checking
are discussed in the next section.
6 Model choice and diagnostics
Factors to consider when selecting a model include: goodness-of-fit measures, model
complexity, interpretability, plausibility of model assumptions, and scientific knowledge,
among other possible considerations. Measures of predictive accuracy usually incorporate
both goodness-of-fit and model complexity. The deviance information criterion (DIC)
suggested by Spiegelhalter et al. (2011) is a measure of predictive performance analogous
to the widely used Akaike information criterion (AIC) and can be easily computed for a
wide range of Bayesian models. An attractive feature of DIC is that it can be used to
compare models with widely different structure and complexity where the number of
model parameters does not have a clear meaning. As with the AIC, the DIC is based on
combining a measure of goodness-of-fit with a penalty term for model complexity. For the
sampling distribution (3) assumed by beanz, the goodness-of-fit is captured by the pos-
terior expected deviance D ¼ E Dðh1; . . .; hGÞjyð Þ where
Dðh1; . . .; hGÞ ¼
XG
g¼1




is a measure of deviance. The ‘‘effective number of parameters’’, pD, is defined as the
difference pD ¼ D  Dðh1; . . .; hGÞ where hg ¼ EðhgjyÞ is the posterior mean of the sub-
group treatment effect hg. The effective number of parameters can be directly computed in
a wide range of hierarchical models such as the basic shrinkage model where the number of
parameters does not have a clear, unambiguous definition. The DIC is then defined as the
posterior expected deviance plus the effective number of parameters
DIC ¼ D þ pD ¼ 2D  Dðh1; . . .; hGÞ:
Lower values of the DIC imply better measures of fit. A rough rule-of-thumb suggested by
Carlin and Louis (2009) is that meaningful differences between DIC values start at dif-
ferences of greater than three to five.
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In total, beanz currently offers seven different Bayesian models for subgroup analysis.
Of these seven different models, the extended Dixon–Simon model had the lowest value of
the DIC when looking at the SOLVD data with the 12 subgroups defined by age, gender
and ejection fraction. The difference in DIC between the basic shrinkage model and the
extended Dixon–Simon model was 2.56. Though the extended Dixon–Simon is best in
terms of DIC, this relatively small difference in DIC suggests that both the basic shrinkage
and extended Dixon–Simon models could be justified as model choices.
While DIC is a useful tool for model comparison, the DIC alone is not necessarily helpful
in checking whether a particular model provides a good fit to the data. Posterior predictive
checks (Rubin 1984 or Gelman 2003) are a useful tool for checking the plausibility of a model
and for uncovering particular features of the observed data that are not captured well by the
model under consideration. In a nutshell, posterior predictive checks are performed by
comparing hypothetical data generated from the fitted model with the observed data. If the
posterior provides a good fit, one should expect samples from the posterior predictive dis-
tribution to resemble the observed data, or at least, one should not expect there to be sys-
tematic discrepancies between the posterior predictive distribution and the observed data.
Posterior predictive checks are often carried out by choosing a particular test statistic TðyÞ or a
collection of test statistics and comparing the posterior predictive distribution of TðyÞ (usually
denoted as p TðyrepÞjyð Þ) with the observed value of TðyÞ. Samples from the posterior pre-
dictive distribution can be used to visually assess whether or not the observed value of the
statistic TðyÞ seems typical of hypothetical replications from the fitted model. More formal
testing approaches involving the computation of posterior predictive p values have been
suggested by others, for example, Meng (1994).
Summary of key factors to consider when using Bayesian methods to analyze heterogeneity of treatment
effects
Model specification
The models described in Jones et al. (2011) and implemented by beanz offer a number of useful options
for subgroup analysis. Parameters for the prior distributions can be chosen using common default
values such as those used in the beanz software, through incorporating external information, or
through knowledge about the scale of the outcome. In all cases, one should ensure that interpretations
of the model parameters are well-understood and that the choice of priors is defensible.
Diagnostics and model criticism
If multiple models are considered, the deviance information criterion (DIC) can be used to compare
model performance. Small differences (less than 3–5) in DIC are often not considered meaningful.
Sensitivity analyses should be conducted by investigating changes in key posterior quantities over a
range of different priors. Looking at posterior inferences in other plausible alternative models can also
serve as a way of examining the sensitivity of the results. Posterior predictive simulations as depicted
in Fig. 5 are a useful tool for checking if replicated data sets from the fitted model seem plausible in
light of the observed data. Notable differences between posterior predictive simulations and the
observed data suggest that one should consider modifying the model.
Reporting and interpreting results
Reporting posterior summaries for all subgroup parameters is often effective for characterizing HTE and
for interpreting particular subgroups effects. Forest plots such as those shown in Figs. 1 and 4 are an
effective way to visually represent this information. Posterior summaries related to many questions of
clinical interest can usually be obtained from the full posterior distribution. For instance, an important
question to consider is often whether or not there are qualitative interactions; that is, are there
subgroups whose treatment effect is in the opposite direction of the average treatment effect? Finally,
for full transparency, one should describe all steps taken in the analysis; for example, one should
describe any changes made to the model during the course of the analysis, or if multiple models were
originally entertained, one should describe why the final model was chosen.
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In the context of the models discussed Sect. 4 where the sampling distribution is
assumed by (3), one can generate a sample h^pred;sg of subgroup effects from the posterior
predictive distribution by first drawing hpost;sg  pðhgjyÞ from the posterior distribution of hg
and then sampling h^pred;sg Normalðhpost;sg ; s2gÞ using the draw from the posterior as the
assumed mean of the normal distribution. A sample from the posterior predictive distri-
bution of TðyÞ is then computed from the individual draws h^pred;s1 ; . . .; h^pred;sG . Figure 5
shows posterior predictive simulations for both the basic shrinkage and extended Dixon–
Simon models, and for each of these models, the median, standard deviation, minimum,
and maximum were chosen as the test statistics TðyÞ to examine. There is no suggestion in
these posterior predictive checks that either of the models is deficient in any particular way.
For both models, the observed values of the test statistics appear to be quite typical values
in terms of the posterior predictive distribution, though the observed standard deviation and
maximum seem to be somewhat more representative of predicted values from the extended
Basic Shrinkage Model
−0.6 −0.4 −0.2 0.0
T(y) = median
Extended Dixon−Simon Model
−0.6 −0.4 −0.2 0.0 0.2
T(y) = median
0.1 0.2 0.3 0.4 0.5 0.6 0.7
T(y) = standard deviation
0.1 0.2 0.3 0.4 0.5 0.6









Fig. 5 Posterior predictive checks. Samples from the posterior predictive distribution using both the basic
shrinkage model and the extended Dixon–Simon model on the SOLVD data. Samples from the posterior
predictive distribution of various test statistics T(y) are shown: median, standard deviation, minimum, and
maximum. For each panel, the solid vertical line represents the observed value of the statistic T(y)
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Dixon–Simon model. If the values of one or more of the test statistics TðyÞ were nearer to
the tails of the posterior predictive distribution, this would be an indication that the model
should be changed in some way or that one should consider an alternative model.
7 Conclusion
The Bayesian approach offers both an effective and practical framework for evaluating
differences in treatment effectiveness due to heterogeneity in patient characteristics.
Bayesian methods have particular advantages in the analysis of HTE as they provide a
flexible framework for synthesizing evidence of all types such as prior information or
information across subgroups. Despite these merits, a number of factors has limited wider
adoption of Bayesian methods including lack of accessible software and concerns about the
choice and impact of priors. We have addressed these concerns by outlining specific
models that can be used to examine HTE and by highlighting the important issues involved
in their implementation. We have also demonstrated these ideas using a case study and a
software tool called beanz, which can be used as a web-server version or as a stand-alone
R package.
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